1Lacey JV Jr,Mink PJ,Lubin JH et al.Menopausal hormone replacement therapy and risk of ovarian cancer.JAMA,2002,288(3):334
2Riman T,Dickman PW,Nisson S et al.Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.J Natl Cancer Inst Oxford,2002,94(7):497
3Sit AS,Modugno F,Weissfeld JL et al.Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma.Gynecol Oncol,2002,86(2):118
4Lee BH,Hecht JL,Pinkus JL et al.WT1,estrogen receptor,and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.Am J Clin Pathol,2002,117(5):745
5Lindgren PR,Cajander S,Backstrom T et al.Estrogen and progesterone receptors in ovarian epithelial tumors.Mol Cell Endocrinol,2004,221(1-2):97
6Leong CT,Ng CY,Ong CK et al.Molecular cloning,characrizaion and isolation of novel speliced variants of the human ortholog of a rat estrogen-regulated membrane-associated protein,uo-44.Oncogene,2004,23(54):8857
7Song J,Fadiel A,Edusa V et al.Estradiol-induced ezrin overexpression in ovarian cancer:a new signaling domain for estrogen.Cancer Lett,2005,220(1):57
8Nakayama K,Takebayashi Y,Nakayama S et al.Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving ciplatin.Cancer Lett,2003,192(2):227
9Skirnisdottir I,Seidal T,Sorbe B et al.The prognostic importance of p53,bcl-2,and bax in early stage epithelial ovarian carcinoma treatment with adjuvant chemotherapy.Int J Gynecol Cancer,2002,12(3):265
10Rattenborg T,Gjermandsen I,Bonefeld-Jorgensen EC.Inhibition of E2-induced expression of BRCA1 by persistent organochlorines.Breast Cancer Res,2002,4(6):12
